Blue Goose Capital
Overview
Blue Goose Capital is a venture capital firm founded in 2018 and located in Cambridge, Massachusetts . The firm focuses on investing in the healthcare sector, specifically targeting biopharmaceutical, data, and medical device companies . Blue Goose Capital initiates its investments with seed capital and is currently managing its second fund, which exclusively invests in U.S. biotechnology firms beginning at the Series A stage . The firm aims to support innovative solutions within the healthcare industry .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Therini Bio | May 2025 | Series A Extension | - |
| Mythic Therapeutics | Dec 2021 | Series B | - |
| ADNTRO GENETICS | Oct 2024 | Seed | Co-investor |
Key People
Doug Zingale
Managing Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Blue Goose Capital based?
Blue Goose Capital is headquartered in Cambridge, Massachusetts, United States.
When was Blue Goose Capital founded?
Blue Goose Capital was founded in 2018.
How many portfolio companies does Blue Goose Capital have?
Blue Goose Capital has 3 portfolio companies in Caplight's dataset.
What are some companies in Blue Goose Capital's portfolio?
Portfolio companies visible on Caplight include Therini Bio, Mythic Therapeutics, ADNTRO GENETICS.
What was Blue Goose Capital's most recent investment shown here?
Blue Goose Capital's most recent investment in this portfolio sample was in Therini Bio in 2025.
What sectors does Blue Goose Capital focus on?
Blue Goose Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does Blue Goose Capital focus on?
Blue Goose Capital typically invests at the Early stage.
What is Blue Goose Capital's AUM?
Blue Goose Capital's assets under management are estimated between $0.0 and $50.0M.